Frontline Ribociclib/Letrozole Improves OS in Postmenopausal HR+ Breast Cancer, Irrespective of Metastatic Site
December 8th 2021
First-line treatment with ribociclib/letrozole improved overall survival over placebo in patients with postmenopausal, hormone receptor–positive, HER2-negative advanced breast cancer, irrespective of metastatic site, number of sites, or prior (neo)adjuvant chemotherapy and endocrine therapy.